AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02637557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IW-3718
Study NCT02637557 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Study NCT02637557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PPI
Description: All participants were taking a standard dose QD PPI (dexlansoprazole, esomeprazole, esomeprazole magnesium, lansoprazole, omeprazole, pantoprazole, pantoprazole sodium sesquihydrate, rabeprazole or rabeprazole sodium) during the study.
Study NCT03881280 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parenting education program
Description: Parenting education program through the app Fammeal. It includes educational content, tailored to parents and centered on positive parenting child-feeding practices. The app will also include a virtual-pet game for children, in order to help them self-regulate their intake.~Through the app, parents will:~* Fill in a registration questionnaire, which will tailor recommendations.~* Receive information and video content recommendations.~* Set goals related to their child's lifestyle and tracking progress.~* Earn points by watching the contents.~* Invite children to play a serious game.~* Exchange messages with other users.~The investigators created a support website that connects to the main server to get data gathered from the mobile app and game.
Study NCT01807156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivozanib
Description: Oral medication given daily. No placebo.
Study NCT01731743 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: AT LISA tri 839MP
Study NCT01074892 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Provera (medroxyprogesterone/progestin)
Description: 10 mg tablet, 1 tablet per day taken 10 days per month Duration is 6 months
Study NCT03395080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Administered by IV infusion
Study NCT03395080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 300mg DKN-01
Description: Administered by IV infusion
Study NCT03395080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 600mg DKN-01
Description: Administered by IV infusion
Study NCT02320773 — intervention group
Intervention type: DRUG
Intervention: Betmiga®
Description: Oral
Study NCT03244631 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lumbar Plexus BLock
Description: Peripheral nerve block
Study NCT03244631 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pericapsular injection
Description: Injection around the area undergoing surgery
Study NCT03264924 — intervention group
Intervention type: BEHAVIORAL
Intervention: IPAIR
Description: Motivational interview training
Study NCT01413750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT01413750 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV
Study NCT01413750 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01413750 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01413750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT01413750 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Given IV
Study NCT01413750 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Administration
Description: Given PO
Study NCT01413750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Given PO
Study NCT01074892 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Provera (medroxyprogesterone)
Description: 10 mg per oral tablet. One tablet per day for 6 months
Study NCT01074892 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mirena (levonorgestrel)
Description: Inserted in the uterine cavity and kept in situ for 6 months
Study NCT02531763 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social incentive intervention
Description: Participant sign a pre-commitment pledge to try to achieve their goal. They are entered into a game with their teammate in which they have the chance to earn points and advance through levels (bronze, silver, gold, platinum). At the end, those in gold or platinum will receive a coffee mug as a reward
Study NCT02237235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMFS-202-302
Description: Active ingredient: L-Threonic acid Magnesium salt.~1 g (2 pills) by mouth once daily in the evening for 9 weeks~Drug: MMFS-302 Active ingredient: L-Threonic Acid Magnesium Salt~1 g (2 pills) by mouth once daily in the morning for 9 weeks
Study NCT02237235 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two tablets by mouth in the morning, and two tablets by mouth in the evening, daily for 9 weeks.
Study NCT01519388 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spontaneous breathing
Description: study of the swallowing of boluses of water and yogurt under spontaneous breathing
Study NCT01519388 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Elysée 150®
Description: Study of the swallowing of boluses of water and yogurt while under mechanical ventilation
Study NCT05566808 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Autologous Costal Cartilage Graft
Description: Subjects undergoing either reconstructive or cosmetic rhinoplasty will choose which graft will be used in their intervention.
Study NCT05566808 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Costal Cartilage Allograft.
Description: Subjects undergoing either reconstructive or cosmetic rhinoplasty will choose which graft will be used in their intervention.
Study NCT01003522 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Arterial puncture
Description: Patients will undergo arterial blood gas sampling from the radial artery. This will be done by experienced doctors who are highly skilled in this procedure.
Study NCT01003522 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Venepuncture
Description: Blood samples for baseline biochemistry, full blood count, and clotting screen will be taken. In patients additionally providing optional consent blood will be taken for laboratory based basic science research into lung cancer carcinogenesis and pharmacogenetics. Blood will be taken by qualified and experienced nurses, doctors and phlebotomists.
Study NCT01003522 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: General anaesthetic
Description: Patients randomised into the stenting arm will undergo rigid bronchoscopy under general anaesthetic.
Study NCT01003522 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Inpatient stays
Description: Patients randomised into the stenting arm will be admitted overnight for the procedure
Study NCT01003522 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Walking test
Description: All patients will be asked to complete a 6 minute walking test at baseline and on day 15. Patients randomised into the stent arm (Arm A) will complete a further 6 minute walking test at 24 hours post-stent
Study NCT01003522 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Spirometry & flow volume loop assessment
Description: All patients will undergo spirometry and flow volume loop assessments at baseline and on day 15.
Study NCT01003522 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Biopsy material
Description: For patients randomised to stenting and giving additional voluntary consent, 2 pairs of biopsies of tumour tissue, and 1 pair of biopsies of normal airways tissue will be taken for basic scientific research into lung cancer carcinogenesis, and pharmacogenetics.
Study NCT04096014 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ensure Enlive
Description: The subjects in the intervention group will receive two Ensure Enlive supplements per day for 180 days.
Study NCT04096014 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Of Care
Description: The subjects in the Standard of care group will continue to receive the standard clinical therapy.
Study NCT04096014 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard Of Care
Description: The subjects in the Standard of care group will continue to receive the standard clinical therapy.
Study NCT03346538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Continuous infusion high-dose MCI-186
Description: intravenous injection
Study NCT03346538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Continuous infusion low-dose MCI-186
Description: intravenous injection
Study NCT03346538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Continuous infusion placebo
Description: intravenous injection
Study NCT03346538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Approved dosing regimen MCI-186
Description: intravenous injection
Study NCT03346538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Approved dosing regimen placebo
Description: intravenous injection
Study NCT04513522 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days
Study NCT04513522 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified days
Study NCT02823821 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Default dialysate sodium concentration of 137mmol/l
Description: Default defined here as use of allocated dialysate sodium concentration for at least 90% of delivered dialysis sessions.
Study NCT02823821 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Default dialysate sodium concentration of 140mmol/l
Description: Default defined here as use of allocated dialysate sodium concentration for at least 90% of delivered dialysis sessions.
Study NCT04524078 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intensive integrated intervention care program
Description: intensive integrated intervention care program \[ICP\] (lifestyle changes, patient education, adherence to practical guidelines) to transient ischemic attack or minor stroke patients would modify a variety of vascular risk factors and therefore should decrease the likelihood of recurrent stroke or vascular events
Study NCT03188796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: oral/enteral loading dose of 37.5 ml MCT including 540,000 IU vitamin D3 followed by 10 drops daily (4000 IU) for 90 days
Study NCT03188796 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral/enteral loading dose of 37.5 ml MCT followed by 10 drops daily for 90 days
Study NCT04070989 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: THA
Description: Pinnacle Acetabular Shell (Sector, Gription, no screws), AltrX Polyethylene Liner and Corail Femoral Stem
Study NCT01927744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 mg/m2 by vein on Day 1 of each 21 day cycle for a maximum of 3 cycles.
Study NCT01927744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 150 mg by mouth daily continuously until the day before surgery.
Study NCT01927744 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 150 mg by mouth daily continuously until the day before surgery.
Study NCT01927744 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Questionnaire completion at baseline, 14 days after treatment completion, and 8 weeks after surgery.
Study NCT01927744 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone Call
Description: Phone call made to patient 1 time each year after the end of treatment visit.
Study NCT01927744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Cisplatin 75 mg/m2 or Carboplatin AUC 6 mg.min/ml by vein on Day 1 of each 21 day cycle for a maximum of 3 cycles.
Study NCT04155333 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: Transcranial direct current stimulation (tDCS) is a form of non-invasive brain stimulation that stimulates the brain through the application of a low-intensity electrical current, typically ranging from 1 to 2 milliamps (mA), via electrodes placed on an individual's scalp. During the active stimulation sessions, 2 mA of stimulation will be applied for 30 minutes. During the sham stimulation session, 2 mA of stimulation will be applied over the course of 90 sec, the electrodes will remain in place for the 30 minute duration.
Study NCT04155333 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: Transcranial direct current stimulation (tDCS) is a form of non-invasive brain stimulation that stimulates the brain through the application of a low-intensity electrical current, typically ranging from 1 to 2 milliamps (mA), via electrodes placed on an individual's scalp. During the active stimulation sessions, 2 mA of stimulation will be applied for 30 minutes. During the sham stimulation session, 2 mA of stimulation will be applied over the course of 90 sec, the electrodes will remain in place for the 30 minute duration.
Study NCT02942628 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vegetarian diet followed by meat diet or vice versa
Description: Half the patients will follow either a vegetarian diet for 6 weeks and the other half will adhere to or a meat-based diet for six weekd. This is followed by a 4 week period where patients eat their usual diet. Thereafter patients initially randomized to a vegetarian diet will follow a meat-based diet for six weeks while the patients initially randomized to meat will follow a vegetarian diet for six weeks.
Study NCT02942628 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vegetarian diet followed by meat diet or vice versa
Description: Half the patients will follow either a vegetarian diet for 6 weeks and the other half will adhere to or a meat-based diet for six weekd. This is followed by a 4 week period where patients eat their usual diet. Thereafter patients initially randomized to a vegetarian diet will follow a meat-based diet for six weeks while the patients initially randomized to meat will follow a vegetarian diet for six weeks.
Study NCT01954758 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: personalized Embryo Transfer (pET)
Study NCT01954758 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Frozen Embryo Transfer (FET)
Study NCT01954758 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fresh Embryo Transfer (ET)
Study NCT00981578 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ExAblate 2100
Description: Conformal Bone System
Study NCT02966418 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mild Hypoxia Preconditioning
Description: Patients will be treated with mild hypoxia ( Note: The oxygen concentration decreased from 20% to 18%, and keeping at 18%)×7 days，twice a day in the morning and in the afternoon before surgery.
Study NCT02966418 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham preconditioning
Description: Patients will be treated with sham preconditioning (oxygen concentration: 21％) ×7 days，twice a day in the morning and in the afternoon before surgery.
Study NCT01086878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cotrimoxazole
Description: Daily oral cotrimoxazole suspension from 1 to 6 months of age at the following weight-based doses:~* less than 5kg: 100mg sulfamethoxazole, 20mg trimethoprim~* greater than 5kg: 200mg sulfamethoxazole, 40mg trimethoprim
Study NCT00424177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eltrombopag
Description: experimental
Study NCT04573543 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Evaluation of the degree of fibrosis and steatosis
Description: The degree of steatosis will be estimated using the controlled attenuation parameter (CAP), a method for grading steatosis by measuring the degree of ultrasound attenuation by hepatic fat using a process based on simultaneous transient elastography (TE) which measures the degree of fibrosis.
Study NCT04573543 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Screening for the components of metabolic syndrome
Description: Anthropometric measures including body mass index (BMI), waist circumference (WC), waist hip ratio (WHR), and waist height ratio (WHtR) will be measured in all patients.~Results of the routine laboratory tests as part of the standard diagnostic procedure will be collected: bilirubin, AST, ALT, GGT, ALP, albumins, WBC, neutrophil-to-lymphocyte ratio, hemoglobin, platelet count, fasting glucose, triglycerides, cholesterol, HDL and LDL. Non-invasive scores of steatosis/fibrosis will be calculated (APRI, FIB4, NAFLD score). Patients will be screened for the components of metabolic syndrome.
Study NCT04573543 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of serum semaphorin concentrations
Description: Semaphorin concentration will be measured in patient sera by ELISA.
Study NCT02150109 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Subjects WITH/WITHOUT Diabetes Use Karajishi Contour BGMS
Description: Untrained subjects WITH and WITHOUT diabetes use Karajishi Contour BGMS (Blood Glucose Monitoring System). Subjects tested capillary fingerstick blood (and study staff tested subject fingerstick blood) using the Karajishi Contour BGMS. All BG results were compared to reference method results obtained with subject capillary plasma. Also, study staff tested subject venous blood and BG results were compared to reference method results obtained from subject venous plasma.
Study NCT02150109 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Subjects WITH Diabetes Use Karajishi Contour BGMS
Description: Untrained subjects WITH diabetes use the Karajishi Contour BGMS (Blood Glucose Monitoring System). Subjects tested capillary fingerstick blood (and study staff tested subject fingerstick blood) using the Karajishi Contour BGMS. All BG results were compared to reference method results obtained with subject capillary plasma. Also, study staff tested subject venous blood and BG results were compared to reference method results obtained from subject venous plasma.
Study NCT00768209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phentermine and Topiramate
Description: Each subject will be dosed with a single oral dose of VI-0521 (PHEN/TPM 15/92 mg).
Study NCT01626677 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CARTISTEM
Description: A single dose of 500㎕/㎠ of cartilage defect
Study NCT01626677 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microfracture
Description: Active control
Study NCT03291873 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PRK
Description: PRK using Alcon-Wavelight Excimer Laser EX 500
Study NCT04573543 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Identification of semaphorin gene polymorphisms
Description: Semaphorin genes will be sequenced to identify semaphorin gene polymorphisms associated with NAFLD.
Study NCT02228967 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SBIRT
Description: SBIRT is an opportunistic approach whereby patients are screened by Health Educators for their alcohol use, and then, taking advantage of a teachable moment, are delivered a brief, motivational intervention matched to their level of risk.
Study NCT03448445 — intervention group
Intervention type: OTHER
Intervention: Usual care setting
Description: usual care settings without any intervention
Study NCT03440502 — intervention group
Intervention type: PROCEDURE
Intervention: spinal anaesthesia
Description: Intrathecal block under strict aseptic conditions will be performed by median approach (L3-4 or L4-5) under sitting position by anesthesiologists . 25 Gauge sprotte spinal needles and 2-3 mLof 0.5% hyperbaric bupivacaine
Study NCT04640623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAR-200
Description: TAR-200 will be administered transuretherally.
Study NCT00655668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide capsules, 25 mg daily for 21 days in each 28 day cycle
Study NCT04640623 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetrelimab
Description: Cetrelimab will be administered.
Study NCT03145181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teclistamab (IV)
Description: Participants will receive IV infusion of Teclistamab.
Study NCT03145181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teclistamab(SC)
Description: Participants will receive SC injection of Teclistamab.
Study NCT02637557 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PPI
Description: All participants were taking a standard dose QD PPI (dexlansoprazole, esomeprazole, esomeprazole magnesium, lansoprazole, omeprazole, pantoprazole, pantoprazole sodium sesquihydrate, rabeprazole or rabeprazole sodium) during the study.